Breaking Finance News

A statement released earlier today by Credit Suisse about Clovis Oncology Inc (NASDAQ:CLVS) bumps the target price to $41.00

Boasting a price of $34.83, Clovis Oncology Inc (NASDAQ:CLVS) traded -3.18% lower on the day. With the last stock price close up 111.60% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Clovis Oncology Inc has recorded a 50-day average of $24.12 and a two hundred day average of $17.55. Volume of trade was up over the average, with 8,169,572 shares of CLVS changing hands over the typical 2,669,770

Indicating as possible upside of 0.18%, Credit Suisse raised the target price of Clovis Oncology Inc (NASDAQ:CLVS) to $41.00

On 8/24/2016, Mizuho Securities released a statement for Clovis Oncology Inc (NASDAQ:CLVS) bumped up the target price from $15.00 to $23.00 that suggested a downside of 0.00%.

Performance Chart

Clovis Oncology Inc (NASDAQ:CLVS)

With a total market value of $0, Clovis Oncology Inc has with a one year low of $11.57 and a one year high of $109.18 .

A total of 8 equity analysts have released a ratings update on CLVS. Two equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, six equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $17.50.

Brief Synopsis About Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *